Frishman W H
Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York 10461.
Am J Cardiol. 1992 Dec 21;70(21):2I-6I. doi: 10.1016/0002-9149(92)90258-z.
The evidence supporting and describing cardioprotective effects of beta-adrenergic blocker treatment is surveyed. Details of the many studies that individually and collectively document the ability of long-term and acute beta-blocker therapy to reduce overall mortality, sudden cardiovascular death, and nonfatal reinfarction in patients surviving or experiencing a myocardial infarction are described. A discussion of the mechanisms by which beta blockers probably and theoretically achieve these benefits includes the suggestion that they may reduce plaque rupture, thus indirectly inhibiting thrombosis. It is also suggested that, in the future, further cardioprotective benefits may accrue to the use of beta blockers in conjunction with thrombolysis and of beta blockers with a duration of action sustained throughout a full 24 hours.
本文综述了支持和描述β-肾上腺素能阻滞剂治疗心脏保护作用的证据。详细介绍了众多研究，这些研究单独或共同证明了长期和急性β-阻滞剂治疗能够降低心肌梗死存活或发作患者的总体死亡率、心源性猝死和非致命性再梗死。对β-阻滞剂可能和理论上实现这些益处的机制进行了讨论，其中包括它们可能减少斑块破裂，从而间接抑制血栓形成的观点。还提出，未来将β-阻滞剂与溶栓治疗联合使用，以及使用作用持续时间达24小时的β-阻滞剂，可能会带来更多的心脏保护益处。
